Today, EPA posted Ebola claims guidance to its Antimicrobial Policy and Guidance Documents Webpage.
At this time, the Agency is not allowing label claims related to antimicrobial product efficacy specifically against the Ebola virus. However, if a product meets CDC guidelines for Ebola virus disinfection, companies can identify such products on websites and through other non-label marketing.
In order to meet CDC guidelines, the product must bear at least one label claim for a non-enveloped virus. Examples of common non-enveloped viruses follow:
Norovirus; hepatitis A virus; rotavirus; adenovirus; poliovirus; parvovirus; rhinovirus; various enteroviruses.
Though not stated by EPA in the guidance, Antimicrobial Test Laboratories believes that products should also be approved for use in hospitals, because the CDC document describes only “hospital disinfectants” and addresses disinfection within the hospital environment. Hospital disinfectants are those effective against both Staphylococcus aureus and Pseudomonas aeruginosa.
Note about EPA guidance: As guidance, the document is not binding; EPA may depart from it where circumstances warrant, without prior notice. Pesticide registrants and applicants may propose alternatives to the recommendations described in the guidance, and the Agency will assess them for appropriateness on a case-by-case basis.